Johnson & Johnson guides to 8.2% adjusted EPS growth at its 2026 midpoint, compared with approximately 7% implied by 2026 ...
Approval based on Phase 3 data showing unprecedented functional cure rates compared to standard of care – – Six-month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results